20-F/A: Cuprina Holdings Files 2025 Annual Report Amendment

Cuprina Holdings (Cayman) Limited has filed an amendment to its 2025 annual report, detailing financial performance, operational updates, and internal control assessments.

Summary

• Cuprina Holdings (Cayman) Limited filed an amendment to its 2025 annual report (Form 20-F/A) on July 1, 2026, to correct and update specific items including financial review, controls, and exhibits.
• The company, based in Singapore, focuses on developing and commercializing innovative products for chronic wound management and the health and beauty sector.
• Revenue for the year ended December 31, 2025, was S$49,894 (US$38,789), a slight increase from S$48,321 in 2024, primarily driven by MEDIFLY product sales.
• The company reported a net loss of S$4,673,447 (US$3,633,248) for the year ended December 31, 2025, a significant increase from S$1,560,535 in 2024, largely due to increased professional fees.
• A material weakness in internal control over financial reporting was identified concerning the documentation of customer contracts, with a remediation plan involving an automated ordering process expected to be operational by the second half of 2026.
• The company completed its Initial Public Offering (IPO) on April 11, 2025, and its Class A Ordinary Shares are traded on The Nasdaq Capital Market under the symbol CUPR.
• Pipeline products include collagen dressings utilizing bullfrog collagen and products using medical leeches, with commercialization expected in 2026-2027, subject to regulatory approval.
• Expansion plans for 2026-2027 include entering markets in the Middle East (GCC) and mainland China.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the significant increase in net loss and operating expenses, despite the successful IPO and modest revenue growth.

Positives

• Revenue saw a modest increase of 3.3% to S$49,894 (US$38,789) for the year ended December 31, 2025, compared to S$48,321 in 2024.
• The number of patients using MEDIFLY products increased from 78 in 2024 to 96 in 2025.
• Gross loss significantly decreased from S$3,024 in 2024 to S$645 (US$501) in 2025, indicating improved cost management relative to revenue.
• Other income increased by 34.8% to S$234,455 (US$182,271) in 2025, largely due to fees from ISO13485 certified facilities.
• Interest expense decreased by 60.4% to S$14,724 (US$11,447) in 2025.
• The company successfully completed its IPO on April 11, 2025, raising S$17,606,040 (US$13,687,351) in gross proceeds.
• Cash and cash equivalents significantly increased to S$3,117,682 (US$2,423,760) as of December 31, 2025, from S$116,472 in 2024.

Negatives

• The company reported a substantial net loss of S$4,673,447 (US$3,633,248) for the year ended December 31, 2025, a significant increase from S$1,560,535 in 2024.
• Selling, general, and administrative expenses surged by 228.5% to S$4,602,300 (US$3,577,937) in 2025, primarily driven by a massive increase in other operating expenses.
• Other operating expenses increased by 588.6% to S$3,674,975 (US$2,857,012) in 2025, largely due to professional fees related to the IPO and business development.
• The company has consistently incurred gross losses since 2024, with a gross loss margin of 1.3% in 2025.
• Net cash used in operating activities was S$9,133,948 (US$7,100,947) in 2025, a substantial increase from S$1,235,981 in 2024.
• A material weakness in internal control over financial reporting was identified regarding the documentation of customer contracts.
• Equity in net earnings of affiliates resulted in a loss of S$63,349 (US$49,249) in 2025.

Risks

• Failure to maintain an effective system of internal controls over financial reporting could lead to inaccurate financial results, prevent fraud, harm the business, and negatively impact the stock price.
• The company's results of operations are expected to continue to be affected by its ability to successfully develop and commercialize pipeline products and obtain regulatory approvals.
• The growth of the chronic wound care market in intended markets is crucial, and the company's financial performance is tied to its ability to capture this growth.
• The company's ability to attract customers and educate healthcare practitioners on the benefits of its products is critical for sustainable revenue growth.
• Government policies and medical insurance coverage significantly impact the medical device industry; changes or discontinuation of favorable policies or lack of inclusion in insurance coverage could adversely affect demand and sales volume.
• The reduction or discontinuation of government grants could materially affect the company's business operations and financial condition.
• Inflationary pressures, if they continue to increase materially, could lead to a loss of sales and customers if costs cannot be passed on.
• The company has limited credit available from vendors and is required to prepay the majority of inventory purchases, constraining cash liquidity.

Future Outlook

The company expects to develop its pipeline chronic wound care products (collagen dressings and leech-based products) over 2026 and 2027, aiming for commercial availability subject to regulatory approval. Expansion into the Middle East (GCC) and mainland China is planned for 2026 and 2027. Development of cosmeceutical products incorporating bullfrog collagen is anticipated between 2026 and 2028. The company believes its existing cash, anticipated financing, and operational cash flow will be sufficient for the next 12 months, but may seek additional funding for investments or acquisitions.

Management Comments

• The company believes it will be able to build upon and leverage its expertise to develop innovative cosmeceutical products in the future.
• Through its robust product pipeline, research and development expertise, in-house manufacturing capabilities and knowledge navigating the complex regulatory approval process, we believe we are well positioned to capture the significant potential growth in the chronic wound care medical device market.
• We believe that we have sufficient working capital for our requirements for at least the next 12 months from the date of this annual report, absent unforeseen circumstances, taking into account the financial resources presently available to us, including cash and cash equivalents on hand, and cash flows from our operations.

Industry Context

StockSavvy.ai notes that Cuprina Holdings operates in the growing chronic wound care market, which is projected to reach US$29.22 billion by 2034. The company's focus on natural source materials and innovative therapies like Maggot Debridement Therapy (MDT) positions it within a segment driven by an aging population and increasing prevalence of lifestyle diseases like diabetes.

Comparison to Industry Standards

• The global chronic wound care market was valued at US$15.27 billion in 2025 and is projected to grow at a CAGR of 7.5% to reach US$29.22 billion by 2034 (Fortune Business Insights).
• The company's revenue growth of 3.3% in 2025, while positive, is modest compared to the overall market growth rate, suggesting a need for accelerated product development and market penetration.
• The significant increase in operating expenses, particularly professional fees, is a common trend for companies transitioning to public status post-IPO, but the magnitude here warrants close monitoring against industry benchmarks for similar-stage companies.

Related Party Transactions

• Repayments of advances from related parties amounted to S$2,691,506 (US$2,092,440) in 2025.
• Amount due to related parties was S$2,934,650 as of December 31, 2025.

Stakeholder Impact

• Shareholders: The significant increase in net loss and operating expenses, coupled with the material weakness in internal controls, may negatively impact shareholder confidence and stock price.
• Employees: Payroll and employee benefits increased by 8.2% in 2025, partly due to bonus payouts and CPF wage ceiling adjustments.
• Customers: The company aims to improve customer contract documentation through a new automated process, potentially leading to clearer terms and smoother transactions.
• Creditors: The company's liquidity appears sufficient for the next 12 months, but the increasing cash burn rate warrants attention.

Next Steps

• Develop and implement an automated ordering process for customer contracts, expected to be fully operational by the second half of 2026.
• Continue development of pipeline chronic wound care products (collagen dressings and leech-based products) for commercialization in 2026-2027.
• Expand sales and establish physical operations in the Middle East (GCC) and mainland China during 2026-2027.
• Explore development of cosmeceutical product candidates incorporating bullfrog collagen, with commercial availability targeted between 2026 and 2028.
• Continue to fund future capital expenditures with existing cash balance and proceeds from the offering.

Key Dates

Recommendation

While the company has achieved its IPO and shown modest revenue growth, the significant increase in net loss and operating expenses, coupled with a material weakness in internal controls, presents considerable risk. The positive aspects of pipeline development and market expansion are overshadowed by the current financial performance and control deficiencies. A 'hold' recommendation reflects a cautious approach, awaiting evidence of improved financial control and profitability before considering a more positive stance.

Keywords

Cuprina Holdings, Form 20-F/A, Annual Report, Chronic Wound Care, Biomedical, Biotechnology, Maggot Debridement Therapy, MEDIFLY, Bullfrog Collagen, Cosmeceuticals, IPO, Nasdaq, Financial Results, Internal Controls, SEC Filing